Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tinzaparin: considerations for use in clinical practice.

Edith A Nutescu1, Nancy L Shapiro, Helen Feinstein

  • 1Department of Pharmacy Practice, College of Pharmacy, The University of Illinois at Chicago, Chicago, IL, USA. enutescu@uic.edu

The Annals of Pharmacotherapy
|November 25, 2003
PubMed
Summary

Tinzaparin is a safe and effective low-molecular-weight heparin for preventing and treating deep-vein thrombosis (DVT). Its once-daily dosing simplifies outpatient treatment for venous thromboembolism (VTE).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Current Landscape of Anticoagulation Stewardship Implementation in the United States and Around the World: An International Survey.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Local ancestry-informed GWAS of warfarin dose requirement in African Americans identifies a CYP2C19 splicing QTL.

American journal of human genetics·2025
Same author

Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients.

Clinical pharmacology and therapeutics·2025
Same author

Care Team Attributes Predict Likelihood of Utilizing Pharmacogenomic Information During Inpatient Prescribing.

Clinical and translational science·2025
Same author

Local ancestry informed GWAS of warfarin dose requirement in African Americans identifies a novel CYP2C19 splice QTL.

medRxiv : the preprint server for health sciences·2025

Area of Science:

  • Pharmacology
  • Thrombosis Management
  • Anticoagulant Therapy

Background:

  • Venous thromboembolism (VTE) poses significant health risks.
  • Effective prevention and treatment strategies are crucial for patient outcomes.
  • Low-molecular-weight heparins (LMWHs) offer advantages over unfractionated heparin (UFH).

Purpose of the Study:

  • To evaluate the safety and effectiveness of tinzaparin for VTE prevention and treatment.
  • To assess tinzaparin's efficacy compared to unfractionated heparin.
  • To review the cost-effectiveness of tinzaparin therapy.

Main Methods:

  • Systematic literature search of MEDLINE and PubMed (1980-2002).
  • Inclusion of English-language articles.
  • Emphasis on randomized controlled trials evaluating safety, efficacy, and cost-effectiveness.

Related Experiment Videos

Main Results:

  • Tinzaparin, an LMWH, inhibits factors Xa and IIa, and releases tissue factor pathway inhibitor.
  • It is indicated for acute symptomatic deep-vein thrombosis (DVT), with or without pulmonary embolism.
  • Once-daily subcutaneous tinzaparin is as effective and safe as UFH for VTE prevention and treatment, requiring minimal monitoring.
  • Favorable cost-benefit ratio observed.

Conclusions:

  • Tinzaparin demonstrates safety and efficacy in DVT prevention and treatment.
  • Consistent once-daily dosing supports outpatient self-administration.
  • Further comparative studies with other LMWHs are warranted.